Last reviewed · How we verify
Platinum, investigator's choice
Platinum compounds form DNA-damaging adducts that cross-link DNA strands, triggering apoptosis in rapidly dividing cancer cells.
Platinum compounds form DNA-damaging adducts that cross-link DNA strands, triggering apoptosis in rapidly dividing cancer cells. Used for Various solid tumors (specific indication determined by investigator choice in clinical trial).
At a glance
| Generic name | Platinum, investigator's choice |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Platinum-based chemotherapy agents, such as cisplatin, carboplatin, and oxaliplatin, bind to DNA and form interstrand and intrastrand cross-links. These cross-links prevent DNA replication and transcription, leading to cell cycle arrest and programmed cell death. The term 'investigator's choice' indicates the specific platinum agent is selected by the treating physician based on the clinical context and patient factors.
Approved indications
- Various solid tumors (specific indication determined by investigator choice in clinical trial)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Myelosuppression
- Nausea and vomiting
- Peripheral neuropathy
- Anemia
- Thrombocytopenia
Key clinical trials
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platinum, investigator's choice CI brief — competitive landscape report
- Platinum, investigator's choice updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI